Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | CPA3 | P15088 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055698 | 0.88 | CYP1A2 (0.33) | ALDH1A1CYP2D6KDM4EPOLBHPGD | |
| SCHEMBL7050211 | 0.83 | SRC (0.41) | SRCNAALAD2CPA3ALDH1A1CYP2D6 | |
| SCHEMBL7049026 | 0.75 | CYP1A2 (0.45) | NAALAD2CYP1A2 | |
| SCHEMBL7049707 | 0.74 | SRC (0.41) | SRCNAALAD2CPA3ALDH1A1CYP2D6 | |
| SCHEMBL7053788 | 0.72 | NAALAD2 (0.40) | SRCNAALAD2CPA3ALDH1A1CYP2D6 | |
| SCHEMBL7053113 | 0.72 | LMNA (0.33) | ALDH1A1CYP2C19FFAR1CYP1A2LMNA | |
| SCHEMBL7049937 | 0.72 | MME (0.44) | NAALAD2CPA3CYP1A2MME | |
| SCHEMBL5217064 | 0.72 | CYP2D6 (0.57) | SRCNAALAD2CPA3ALDH1A1CYP2D6 | |
| SCHEMBL7048024 | 0.71 | NAALAD2 (0.39) | SRCNAALAD2CPA3ALDH1A1CYP2D6 | |
| SCHEMBL7051349 | 0.71 | CYP1A2 (0.41) | CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658340-B | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-117658340-A | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| CN-119371008-B | Composite carbon source for sewage treatment and preparation method thereof | 江西建衡环保科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119371008-A | Composite carbon source for sewage treatment and preparation method thereof | 江西建衡环保科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-117658340-B | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-117658340-B | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-117658340-A | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117658340-A | Composite carbon source for sewage treatment and preparation method thereof | 西安益维普泰环保股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | SRC 2662/4885NAALAD2 1/4885CPA3 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.